Join us as we talk with Dr. Jatin Shah about his many open mutliple myeloma clinical trials at MD Anderson. With a wave of new approaches just presented at ASH, Dr. Shah discusses the wide variety of clinical trial offerings for myeloma patients (from newly diagnosed to relapsed or refractory) that include the use of monoclonal antibodies and other cell signaling inhibitors that are now being tested in the mix with existing therapies.
Sorry we couldn't complete your registration. Please try again.
You must accept the Terms and conditions to register